Profile
Mr. Edouard Caram joined Sofinnova Partners as analyst in Life Science in November 2007.
Prior to that, he was the European Marketing Manager of PDL BioPharma, a Silicon based Biopharmaceutical Company dedicated to the discovery, development and marketing of Humanized Monoclonal Antibodies for Inflammatory Bowel Diseases, Solid Tumour and Multiple Myeloma.
Mr. Caram started his career as Manager in Business Development (licensing and acquisition) at Janssen-Cilag (Johnson and Johnson), with a particular emphasis on two growing franchises: Metabolism (diabetes/ obesity) and Virology.
Edouard holds a Master of Biochemistry (University Paris VII), a MBA from Ecole Supérieure des Affaires in Beirut (ESCP-EAP), a Master of Finance from Institut d’Etudes Politique de Paris (Sciences-Po) and Executive Education programs from The Wharton School.
Former positions of Edouard Caram
| Companies | Position | End |
|---|---|---|
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Private Equity Analyst | 2009-10-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Finance |
- Stock Market
- Insiders
- Edouard Caram
